1. Home
  2. MAIA vs BEDU Comparison

MAIA vs BEDU Comparison

Compare MAIA & BEDU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MAIA
  • BEDU
  • Stock Information
  • Founded
  • MAIA 2018
  • BEDU 1994
  • Country
  • MAIA United States
  • BEDU United Kingdom
  • Employees
  • MAIA N/A
  • BEDU N/A
  • Industry
  • MAIA Biotechnology: Pharmaceutical Preparations
  • BEDU Other Consumer Services
  • Sector
  • MAIA Health Care
  • BEDU Real Estate
  • Exchange
  • MAIA Nasdaq
  • BEDU Nasdaq
  • Market Cap
  • MAIA 46.7M
  • BEDU 47.7M
  • IPO Year
  • MAIA 2022
  • BEDU 2017
  • Fundamental
  • Price
  • MAIA $1.85
  • BEDU $1.80
  • Analyst Decision
  • MAIA
  • BEDU
  • Analyst Count
  • MAIA 0
  • BEDU 0
  • Target Price
  • MAIA N/A
  • BEDU N/A
  • AVG Volume (30 Days)
  • MAIA 543.2K
  • BEDU 3.4K
  • Earning Date
  • MAIA 08-08-2025
  • BEDU 08-01-2025
  • Dividend Yield
  • MAIA N/A
  • BEDU N/A
  • EPS Growth
  • MAIA N/A
  • BEDU N/A
  • EPS
  • MAIA N/A
  • BEDU N/A
  • Revenue
  • MAIA N/A
  • BEDU $224,321,752.00
  • Revenue This Year
  • MAIA N/A
  • BEDU N/A
  • Revenue Next Year
  • MAIA N/A
  • BEDU N/A
  • P/E Ratio
  • MAIA N/A
  • BEDU N/A
  • Revenue Growth
  • MAIA N/A
  • BEDU N/A
  • 52 Week Low
  • MAIA $1.40
  • BEDU $1.35
  • 52 Week High
  • MAIA $4.24
  • BEDU $2.41
  • Technical
  • Relative Strength Index (RSI)
  • MAIA 53.36
  • BEDU 54.28
  • Support Level
  • MAIA $1.82
  • BEDU $1.70
  • Resistance Level
  • MAIA $2.03
  • BEDU $1.80
  • Average True Range (ATR)
  • MAIA 0.12
  • BEDU 0.04
  • MACD
  • MAIA 0.02
  • BEDU -0.00
  • Stochastic Oscillator
  • MAIA 58.14
  • BEDU 53.57

About MAIA MAIA Biotechnology Inc.

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.

About BEDU Bright Scholar Education Holdings Limited each representing four

Bright Scholar Education Holdings Ltd operates as an education service provider. It is engaged in the provision of education services, including complementary education services, operation services for domestic schools, and education programs and services including independent schools and colleges in United Kingdom (the UK) and the United States (the U.S.) Kingdom. It nearly eight overseas school located in the United Kingdom and the United States. It has three reportable segments, including Overseas Schools, Complementary Education Services, and K-12 Operation Services. Key revenue is generated from Overseas Schools. From a geographical perspective: Key revenue is generated from China following UK, U.S., Canada and Singapore.

Share on Social Networks: